Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

109 results about "Streptozotocin" patented technology

Streptozotocin or streptozocin (INN, USP) (STZ) is a naturally occurring alkylating antineoplastic agent that is particularly toxic to the insulin-producing beta cells of the pancreas in mammals. It is used in medicine for treating certain cancers of the islets of Langerhans and used in medical research to produce an animal model for hyperglycemia in a large dose, as well as type 2 diabetes or type 1 diabetes with multiple low doses.

Fatty-liver-related liver cancer model building method based on knockout mice

The invention relates to a fatty-liver-related liver cancer model building method based on knockout mice. The method is characterized in that APOE-/- and LDLR-/- knockout mice including female mice and male mice are selected, the female mice and the male mice are matched in number, and double knockout mice are obtained; a primer is designed, and the genotypes in mice are identified through a PCR (polymerase chain reaction) system; the PCR (polymerase chain reaction) system comprises an ApoE gene identification PCR conditions and LDLR gene identification PCR conditions; the double knockout mice are pregnant, and suckling mice are obtained; streptozotocin is injected to the suckling mice, the suckling mice begin a high-fat diet after ablactation, and finally the suckling mice surfer from liver cancer; it is identified that the suckling mice begin the high-fat diet after ablactation, fatty liver occurs six weeks later, NASH occurs 8-10 weeks later, dysplastic nodule occurs 13-16 weeks later, and the liver cancer occurs 18-24 weeks later. The occurrence rate of the liver cancer is about 100% 24 weeks later. The time when pure-gene APOE-/- and LDLR-/- knockout mice suffer from NASH and HCC due to the high-fat diet is advanced by 24-30 weeks, and the occurrence rate is high.
Owner:施军平

RH (Rhein) liposome nanoparticles with kidney targeted distribution characteristics and application

The invention relates to RH (rhein) liposome nanoparticles with kidney targeted distribution characteristics and an application of the RH liposome nanoparticles. The lipid capsule nanoparticles have the characteristics of higher encapsulation efficiency and drug loading capacity for RH, uniform particle size distribution, slow release with adoption of in-vitro release, rapid cell uptake, avoidanceof entering lysosome and good biological safety. In a streptozotocin-induced diabetic nephropathy mouse model, KLPPR (Kidney targeting peptide modified Liposomal PCL-PEI nanoparticle loading Rhein) has the good kidney targeted distribution characteristics, can significantly improve a plurality of pathological indexes of the diabetic nephropathy mouse and alleviate and reverse deterioration of thecourse of diabetic nephropathy, and effectively improves the therapeutic effect of RH on diabetic nephropathy. According to the nanoparticles, a brand-new strategy is provided for targeted treatmentof diabetic nephropathy, clinical transformation of RH drugs is further promoted, and an important reference is provided for research of novel nano-preparations of RH and similar drugs.
Owner:浙江省中医院、浙江中医药大学附属第一医院

Method for studying mechanism of gynura divaricata influencing inflammatory factors in type-II diabetic mice

The invention discloses a method for studying the mechanism of gynura divaricata influencing inflammatory factors in type-II diabetic mice, and relates to diabetes research. The method comprises the following steps: adaptively feeding 50 mice for one week, then randomly dividing into a blank control group and a model group, and feeding with normal feed and high-fat and high-sugar feed; after feeding for 4 weeks, fasting and but feeding with water for 12h overnight, weighing and marking; and injecting STZ for three days, fasting and but feeding with water for 12h overnight, firstly experimenting in advance by using a glucometer and test paper, then monitoring the tail blood glucose of the mice by using a microglucometer, and determinating, wherein the fasting blood glucose being greater than or equal to 11.1mmol/L is used as a model standard for the type-II diabetes. Type-II diabetes mouse models are replicated through coordination of a high-fat diet and intraperitoneal injection of streptozotocin, and influence on the inflammatory factors in the mice after intervention of the fresh gynura divaricate is evaluated, so that a clearer theory is provided for the treatment of the type-II diabetes by the gynura divaricate and further development of a Guangxi-characteristic Chinese herbal medicine.
Owner:GUANGXI UNIV OF CHINESE MEDICINE

Mirabilis jalapa root general flavone extractive for preventing and curing diabetes mellitus type 2 and complication and preparation method and application thereof

The invention relates to the field of medicine, in particular to a mirabilis jalapa root general flavone extractive for preventing and curing diabetes mellitus type 2 and a preparation method and application thereof. In the extractive, the content of general flavone is greater than 40%, when the dosage of the extractive is 100 mg/kg, the extractive has obvious effects on decreasing the content ofblood glucose, total cholesterol, triglycerides, tissue triglycerides and increasing glycogen content, prophylaxis and remedial medication have similar effects on blood glucose and lipid lowering of diabetes mellitus type 2 induced by streptozotocin, also reduce blood glucose and lipid type 2 diabetes (db/db) mice of gene knockout, and do not affect glucolipid metabolism of normal mice. Accordingto the preparation method of mirabilis jalapa root general flavone extractive, mirabilis jalapa root general flavone is separated and purified by macroporous adsorption resin, in the prepared mirabilis jalapa root general flavone extractive, the content of the general flavone is greater than 40 %, the transfer rate reaches up to 70 %, and the yield rate can reach up to 2 %.
Owner:THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV

Polygonatum kingianum solid beverage assisting in decreasing blood sugar and preparation method thereof

The invention discloses a polygonatum kingianum solid beverage assisting in decreasing blood sugar. The polygonatum kingianum solid beverage assisting in decreasing the blood sugar is prepared from the following components in parts by mass: 55.00-75.50 parts of polygonatum kingianum aqueous extract, 27.00-38.00 parts of polygonatum kingianum polysaccharide, 0.60-4.00 parts of stevioside, 1.30-12.00 parts of citric acid and 0.40-0.80 part of magnesium carbonate. The invention further discloses a preparation method of the solid beverage. The preparation method of the solid beverage comprises thesteps of preparing, weighing, mixing and granulating of the polygonatum kingianum aqueous extract and the polygonatum kingianum polysaccharide and the like. The main active ingredient, the polygonatum kingianum aqueous extract, has antioxidant activity and alpha-glucosidase inhibition, the polygonatum kingianum polysaccharide can reduce fasting a blood glucose level of streptozotocin-induced diabetic mice and relieve the symptoms of "drink more, eat more, urinate more and weight loss" in the diabetic mice. The solid beverage is reasonable in formula, has a better effect in assisting in decreasing the blood sugar, is easy to carry and store, and all quality indexes meet the requirements of standards and specifications such as "solid beverage".
Owner:SHAANXI NORMAL UNIV

Neo-islets comprising stem and islet cells and treatment of diabetes mellitus therewith

Described are Neo-Islets comprising: a) dedifferentiated islet cells and mesenchymal and / or adipose stem cells; or b) redifferentiated islet cells and mesenchymal and / or adipose stem cells where the cells have been treated so as to facilitate redifferentiation. Further described herein are methods of generating Neo-Islets, the methods comprising: culturing a) dedifferentiated islet cells and mesenchymal and / or adipose stem cells; or b) redifferentiated islet cells and mesenchymal and / or adipose stem cells; on a surface that promotes the formation of cell clusters. Also described are methods of treating a subject, the methods comprising: providing to the subject Neo-Islets described herein. Additionally described are methods of treating a subject suffering from Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, and other types of insulin-dependent diabetes mellitus, or impaired glucose tolerance by providing to the subject Neo-Islet as described herein. Additionally described are methods of treatment in which intraperitoneal administration of islet-sized Neo-Islets composed of high numbers of mesenchymal stem cells and cultured islet cells, durably and reversibly treats, without hypoglycemia, both streptozotocin-induced and spontaneous Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, and other types of insulin-dependent diabetes mellitus, or impaired glucose tolerance.
Owner:SYMBIOCELLTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products